Roivant Sciences (ROIV) EBT (2020 - 2025)
Roivant Sciences (ROIV) posted EBT of -$718.7 million for Q4 2025, down 351.87% on a QoQ basis from -$159.0 million in Q3 2025, and down 50.18% year-over-year from -$1.4 billion in Q4 2024.
Roivant Sciences (ROIV) EBT (2020 - 2025) Analysis & Trends
Roivant Sciences' EBT history runs 6 years deep, the most recent figure standing at -$718.7 million for Q4 2025.
- Quarterly EBT fell 50.18% year-over-year to -$718.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.6 billion (down 136.69% YoY) and the FY2026 annual result came in at -$264.6 million, up 61.18% from the prior year.
- EBT was -$718.7 million for Q4 2025 at Roivant Sciences, down from -$159.0 million in the prior quarter.
- Across five years, EBT topped out at $5.2 billion in Q4 2023 and bottomed at -$1.0 billion in Q4 2022.
- A 5-year average of $3.3 million and a median of -$269.3 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2021 — EBT slumped 1394.75% — and 2023, when it jumped 592.87%.
- Roivant Sciences' EBT stood at -$632.3 million in 2021, then plunged by 65.37% to -$1.0 billion in 2022, then soared by 592.87% to $5.2 billion in 2023, then sank by 109.29% to -$478.5 million in 2024, then sank by 50.18% to -$718.7 million in 2025.
- Business Quant data shows ROIV's EBT at -$718.7 million in Q4 2025, -$159.0 million in Q3 2025, and -$269.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -718.68 Mn |
| Sep 30, 2025 | -159.04 Mn |
| Jun 30, 2025 | -269.26 Mn |
| Dec 31, 2024 | -478.54 Mn |
| Sep 30, 2024 | -224.38 Mn |
| Jun 30, 2024 | -19.64 Mn |
| Dec 31, 2023 | 5.15 Bn |
| Sep 30, 2023 | -241.41 Mn |
| Jun 30, 2023 | -326.09 Mn |
| Dec 31, 2022 | -1.05 Bn |
| Sep 30, 2022 | -313.76 Mn |
| Jun 30, 2022 | -349.79 Mn |
| Dec 31, 2021 | -632.27 Mn |
| Sep 30, 2021 | -225.24 Mn |
| Jun 30, 2021 | -100.99 Mn |
| Dec 31, 2020 | -275.82 Mn |
| Sep 30, 2020 | -52.79 Mn |
| Jun 30, 2020 | -6.76 Mn |